[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphedema\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphedema":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,50,0,25,[9,44,79,107,130,155,183,208,222,242,263,296,324,349,382,411,431,442,469,488,516,535,556,577,598],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100053425","a-post-market-real-world-experience-expanding-access-to-care-by-incorporating-the-symani-surgical-system-and-enabling-surgeons-100053425",false,"NCT06725030","A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons","PRECISE: A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons","PRECISE","Pre Operative Inclusion Criteria:\n\n1. At least 22 years of age\n2. Patient agrees to participate in the study, return for all required follow-up visits, complete all study procedures, and has willingly provided written informed consent after receiving all information related to the study, its requirements, and the robotic assisted procedure\n3. Patient has a clinical indication for a microsurgical anastomosis of vessels between 0.1 and 2.5 mm in conjunction with open free-flap surgery of the breast or extremities and\u002For lymphovenous anastomosis surgery of the extremities\n4. Investigator deems the candidate acceptable for free flap transfer surgery and\u002For lymphovenous anastomosis surgery with a robotic assisted microsurgical anastomosis in accordance with the Symani System's Instructions for Use (IFU)\n\nCohort Specific Pre- Operative Inclusion Criteria:\n\nFree Tissue Transfer Surgery: N\u002FA\n\nLymphovenous Anastomosis Surgery\n\n1. Swelling of one limb that is not completely reversed by elevation or compression\n2. Stage I-II lymphedema at screening, based on the International Society of Lymphology (ISL) staging system\n3. At least one of the following positive quantitative measurements:\n\n   1. Volumetry differential between affected limb and contralateral limb must be at least 10% of the other\n   2. Bioimpedance (L-Dex) differential, if feasible, between affected limb and contralateral limb of at least 10 units\n4. Completion of a full course of complete decongestive therapy (CDT), according to ISL guidelines, for at least 12 weeks prior to screening, including use of compression garments for at least 12 weeks without change in regimen\n5. Willingness to comply with recommended regimen of self-care, with consistent use of appropriately sized compression garments from screening through the entire study duration (through the 3-month follow-up visit).\n\nPre-Operative Exclusion Criteria:\n\n1. Patients who are incapable and\u002For unwilling to provide informed consent\n2. Active systemic infection under treatment with intravenous antibiotics\n3. Clinically significant cardiovascular, digestive, respiratory, endocrine, or central nervous system disorders, previous mental disorders, or other disorders that may significantly affect the data collection or the ability to comply with the protocol per the investigators discretion\n4. Known history of significant bleeding, coagulopathy, or Von Willebrand's disease\n5. Patients with implanted pacemaker\n6. Planned vein graft\n7. Currently receiving chemotherapy or radiation therapy\n8. History of chronic kidney disease\n9. History of chronic liver disease\n10. Currently enrolled in any other investigational clinical studies that the investigator believes may impact patient safety or outcomes\n11. Patients belonging to vulnerable populations, such as pregnant women, or ineligible to participate for other reasons in the judgement of the investigator\n\nCohort Specific Pre-Operative Exclusion Criteria:\n\nFree Tissue Transplant Surgery:\n\n1. Patients with buried flaps\n2. Multiple flaps planned for the procedure\n\nLymphovenous Anastomosis Surgery:\n\n1. Patients \\> 75 years of age\n2. Patients with prior lymphatic reconstruction surgery\n3. Patients with venous edema (arising from increased capillary filtration)\n4. Patients with other medical conditions that could lead to acute limb edema, such as (but not limited to) acute venous thrombosis or heart failure\n5. Patients with other medical conditions that could result in symptoms which overlap symptoms of lymphedema\n6. Current infection in the affected limb\n7. Patients who experience more than one episode of cellulitis in a six month period over the past two years\n8. Current evidence or a history of malignancy within the past 6 months (if the participant has undergone cancer treatment, this must have been completed \\> 6 months prior to enrollment)\n9. Known iodine sensitivity\n10. Patient's lymphatic disease is due to lipedema\n11. Patients with bilateral lymphedema or lymphedema in multiple anatomical locations\n\nIntra Operative Exclusion Criteria:\n\n1. Any presenting condition discovered intraoperatively that, in the opinion of the investigator, would make participating in this study not in the patient's best interest\n2. The patient does not have at least one robotic stitch attempted during the index procedure","ALL","22 Years",{"count":21,"type":22},455,"ESTIMATED","OBSERVATIONAL","The objective of this study is to evaluate the Symani System's safety and effectiveness for microsurgical anastomosis during free tissue transfer surgery and lymphovenous anastomosis surgery.\n\nThe primary endpoints are:\n\n* Effectiveness- Rate of intraoperative anastomosis patency at first attempt.\n* Safety- Freedom from device-related adverse events.\n\nParticipants will receive treatment as standard of care and be asked to:\n\n* Allow the researchers to access and use their information.\n* If participants are undergoing a lymphedema procedure, they will be asked to undergo a questionnaire as part of the study.\n* Participants will be asked to comply with the follow-up visits and complete all study procedures\u002Fquestionnaires as outlined in the protocol.",[26,27,28,29,30],"Open Surgery","Lymphedema","Free Tissue Transfer","Microsurgery","Anastomosis, Surgical","RECRUITING","2026-07-10",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":35},"2025-09-22",{"date":39,"type":22},"2027-12-01",{"name":41,"class":42},"MMI (Medical Microinstruments, Inc.)","INDUSTRY",6,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":56,"conditions":57,"keywords":68,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100053937","screening-for-bcrl-in-targeted-therapy-for-breast-cancer-100053937","NCT05142800","Screening For BCRL In Targeted Therapy For Breast Cancer","Screening for Edema and Breast Cancer-Related Lymphedema in Patients Undergoing Targeted Therapy for Breast Cancer","Inclusion Criteria:\n\n* Subjects who are receiving treatment in the MGH Breast Cancer Center who are enrolled in a DF\u002FHCC-regulated targeted therapy trial for the treatment of early or metastatic breast cancer or patients being treated with a targeted therapy that may alter their risk of developing edema or BCRL will be eligible.\n* Subjects that will be eligible for the study include:\n* Females between 18 and 80 years of age\n* With a history of breast cancer\n* 4 weeks or more post-surgery\n* With or without edema\n* Undergoing treatment with targeted therapy for early or metastatic disease.\n\nExclusion Criteria:\n\n\\- Patients who cannot attain 90 degrees of shoulder abduction (position of measurement with Perometer).","FEMALE","18 Years","80 Years",{"count":55,"type":22},261,"This a prospective, longitudinal study designed to track edema and Breast Cancer Related Lymphedema (BCRL) onset in breast cancer patients taking targeted therapy treatments for early and metastatic breast cancer.\n\nA Perometer and Sozo devise will be used to measure volume changes",[27,58,59,60,61,62,63,64,65,66,67],"Lymphedema Arm","Lymphedema of Upper Arm","Lymphedema of Upper Limb","Lymphedema of the Hands","Edema","Edema Arm","Breast Cancer Lymphedema","Breast Cancer Metastatic","Breast Cancer Stage","Breast Cancer",[27,58,59,60,61,62,63,64,65,66,67],"2026-07-09",{"date":34,"type":35},{"date":72,"type":35},"2018-12-13",{"date":74,"type":22},"2026-09-30",{"name":76,"class":77},"Massachusetts General Hospital","OTHER",1,{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":97,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":78},"100054093","clinical-lymphedema-evaluation---advancing-reconstruction-of-head-and-neck-lymphatics-with-symani-100054093","NCT07311876","Clinical Lymphedema Evaluation - Advancing Reconstruction of Head and Neck Lymphatics With Symani","CLEAR","Inclusion Criteria:\n\n1. At least 22 years of age\n2. Patients with acquired head and neck lymphedema with external lymphedema or both external and internal lymphedema\n3. Patient agrees to participate in the study, return for all required follow-up visits, complete all study procedures, and has willingly provided written informed consent after receiving all information related to the study, its requirements, and the robotic-assisted procedure\n4. Patient has a clinical indication for a microsurgical anastomosis of vessels between 0.1 and 2.5 mm in conjunction with lymphatic reconstruction of the head and neck\n5. Patient has been compliant with complete decongestive therapy (CDT) for at least 4 weeks\n6. Patient has undergone lymphatic mapping of the head and neck and functional lymphatic structures for reconstruction have been identified\n7. Investigator deems the candidate acceptable for lymphatic reconstruction with a robotic-assisted microsurgical anastomosis in accordance with the Symani System's Instructions for Use (IFU)\n8. Willingness to comply with recommended regimen of self-care, with consistent use of manual lymph drainage and\u002For appropriately sized compression garments from screening through the entire study duration (through the 6-month follow-up visit).\n\nExclusion Criteria:\n\n1. Patient who is incapable and\u002For unwilling to provide informed consent\n2. Patients with irreversible head and neck lymphedema, defined as stage 3 of the MD Anderson Cancer Center Head and Neck Lymphedema Rating Scale\n3. Active systemic infection under treatment with intravenous antibiotics\n4. Clinically significant cardiovascular, digestive, respiratory, endocrine, or central nervous system disorders, previous mental disorders, or other disorders that may significantly affect the data collection or the ability to comply with the protocol per the investigator's discretion\n5. Known history of significant bleeding, coagulopathy, or Von Willebrand's disease\n6. Currently receiving chemotherapy or radiation therapy (uncontrolled tumor)\n7. A history of malignancy or cancer treatment within the past 6 months (tumor control)\n8. Patient with unsatisfactory manual lymphatic drainage and\u002For compression garments for at least six months\n9. Patient with prior lymphatic reconstruction in the targeted head \\& neck area\n10. Patient's lymphatic disease is due to lipedema\n11. Patients with other medical conditions that could result in symptoms which overlap symptoms of lymphedema (e.g., thrombosis in the external or internal jugular vein)\n12. Current infection in the head \\& neck area in which lymphedema is present\n13. Currently enrolled in any other investigational clinical studies that the investigator believes may impact patient safety or outcomes\n14. Patient is ineligible to participate for other reasons in the judgement of the investigator",{"count":87,"type":22},30,"INTERVENTIONAL",[90],"NA","The objective of this study is to evaluate the Symani System's safety and effectiveness for microsurgical anastomosis during open lymphatic reconstruction in the head and neck.",[27,93,94,95,96],"Lymphedema of Face","Internal Lymphedema","External Lymphedema","Lymphedema of Neck",[98,99,100],"lymphedema","head and neck lymphedema","symani",{"date":34,"type":35},{"date":103,"type":35},"2026-06-19",{"date":105,"type":22},"2028-02-01",{"name":41,"class":42},{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":88,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":78},"100467433","lympha-procedure-for-the-prevention-of-lymphedema-after-axillary-lymphadenectomy-100467433","NCT05366699","LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy","A Randomized Clinical Trial of the LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy","Inclusion Criteria:\n\n* Ages 18 to 75 years (inclusive)\n* Patients undergoing unilateral or bilateral breast cancer related axillary lymphadenectomy\n* Free of distant metastasis in preoperative screening\n* Histology results of axillary lymph nodes could be either Negative or Positive\n* Patients who undergo preoperative chemotherapy can be included\n* Willingness and ability to provide written informed consent\n* Willingness and ability to comply with all study procedures\n\nExclusion Criteria:\n\n* Primary lymphedema of the affected upper limb\n* Secondary lymphedema of the affected limb prior to the lymphadenectomy\n* Radiotherapy at the axilla before the study \u002F surgery\n* Allergic reaction to porcine collagen or ICG\n* Receiving radiation therapy to the involved nodal basin in a period less than 4 weeks after the surgery\n* Concurrent participation in a clinical trial of any other investigational drug or therapy, regardless of indication, within 1 month before screening\n* Other medical condition that could lead to limb edema, such as (but not limited to primary lymphedema or acute venous thrombosis\n* Other medical condition that could result in symptoms overlapping those of lymphedema in the affected limb (e.g., pain, swelling, decreased range of motion)\n* Either of the following, at the time of baseline evaluation: ipsilateral:contralateral limb volume ratio\\>1.1 or R0 bioimpedance ratio \\> 1.106 when the nondominant limb is at risk, and 1.134 when the dominant limb is at risk.\n* Life expectancy \\\u003C 2 years for any reason\n* Pregnancy or nursing\n* Substance abuse (such as alcohol or drug abuse) within 6 months prior to screening\n* Severe psychiatric disease\n* Significant or chronic renal insufficiency (defined as serum creatinine \\> 2.5 mg\u002FdL or an estimated glomerular filtration rate \\[eGFR\\] \\\u003C 30 mL\u002Fmin at screening) or requires dialytic support\n* Hepatic dysfunction, defined as alanine transaminase (ALT) or aspartate transaminase (AST) levels \\> 3 × upper limit of the normal range (ULN) and\u002For bilirubin level \\> 2 × ULN at screening\n* Absolute neutrophil count \\\u003C 1500 mm3 at screening\n* Hemoglobin concentration \\\u003C 9 g\u002FdL at screening\n* Any reason (in addition to those listed above) that, in the opinion of the investigator, precludes full participation in the study","75 Years",{"count":116,"type":22},80,[90],"Lymphedema is a chronic, progressive, and debilitating condition that occurs with disruption or obstruction of the lymphatic system, which commonly occurs a result of breast cancer therapy. The purpose of this study is to determine if the use of a low risk lymphatic reconstruction procedure at the time of axillary lymph node dissection will reduce the risk of developing lymphedema.\n\nAdditionally, to determine if this procedure improves objective outcomes of lymphedema and patient quality of life",[120,27],"Lymphedema, Breast Cancer","2026-06-18",{"date":123,"type":35},"2026-06-23",{"date":125,"type":35},"2021-09-10",{"date":127,"type":22},"2030-06-01",{"name":129,"class":77},"Stanford University",{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":154},"100266137","lymphedema-surveillance-study-100266137","NCT02743858","Lymphedema Surveillance Study","A Prospective Surveillance Program for Assessment and Treatment of Breast Cancer-Related Lymphedema After Axillary Lymph Node Dissection","Inclusion Criteria:\n\n* Female breast cancer patients over the age of 18\n* Patients consenting for unilateral axillary lymph node dissection (ALND) (prior history of sentinel lymph node biopsy allowed if \\\u003C6 months from consent)\n* Patients consenting for unilateral sentinel lymph node biopsy (SLNB) and possible ALND are eligible for initial entry into the study, but will become ineligible if ALND is not performed\n* Initially consented patients, treated with SLNB alone, who were originally considered ineligible to continue on study, will be approached for re-enrollment\n* Patients who self-identify as Black or White consenting for unilateral ALND or possible ALND will be approached for enrollment onto translational study (Cohort 3)\n\nExclusion Criteria:\n\n* Male breast cancer patients\n* Patients consenting for bilateral axillary surgery\n* Patients with prior history of surgical excision of one or more axillary lymph nodes or SLNB, performed \\>6 months from date of consent\n* Patients with prior history of ALND\n* Patients with no breast surgery performed at MSK",{"count":138,"type":22},1250,"This study is being done to find out how many women develop lymphedema after an axillary lymph node dissection. The investigators also want to look for reasons why some women get lymphedema and others don't. Specifically, the investigators want to do tests on the breast tissue that is removed at the time of surgery to see if they can identify inflammation in the breast tissue, which may increase a woman's risk for lymphedema. The investigators will also ask the patient to answer questions to see how much their quality of life is affected by lymphedema, and whether this study can help women by detecting lymphedema earlier.",[67,27],[27,142,143,144],"Surveillance Program","Axillary Lymph Node Dissection","16-220","2026-05-01",{"date":147,"type":35},"2026-05-07",{"date":149,"type":35},"2016-04",{"date":151,"type":22},"2027-04",{"name":153,"class":77},"Memorial Sloan Kettering Cancer Center",7,{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":88,"phases":165,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":78},"100635871","the-effect-of-resistance-exercise-in-patients-with-lower-limb-lymphedema-the-lymphex-study-100635871","NCT07558317","The Effect of Resistance Exercise in Patients With Lower Limb Lymphedema (the LymphEx Study)","The Effect of Resistance Exercise in Patients With Lower Limb Lymphedema - With and With-out Compression - a Randomized Controlled Trial (the LymphEx Study)","LymphEx","Inclusion Criteria:\n\n* verified diagnosis of lymphedema of the lower limb\n* completed compression bandaging\n* adherence to compression garment in daytime (minumum 5-6 days per week)\n* calf circumference \\> 35 and \\\u003C75 cm\n\nExclusion Criteria:\n\n* severe neuropathy of the lower leg\n* severe skin problems or wounds at the lower leg\n* cellulitis, DVT or acute injuries of the lower limb \\\u003C 2 months prior to inclusion\n* ongoing adjuvant treatment for cancer",{"count":164,"type":22},36,[90],"The aim of the study is to investigate the short-term (within 2 weeks) effects of resistance exercise with and without compression garments on lower limb lymphedema(LLL). Additionally, the study will explore the immediate response in LLL to resistance exercise (2 hours and 24 hours post-exercise).\n\nParticipants will continously wear a circumfencential sensor at the calf (CIMON from Icompression) under a compression garment and an activity tracker (SENS Motion from SENS Innovation Aps) at the thigh for 3 periods (two with supervised exercise sessions of 2 weeks and one control period).\n\nParticipants will attend supervised resistance exercise 2-3 times per week for 2 periods of 2 weeks (one with compression garment and one without). Assessments with the principal investigator will be scheduled before and after every 2 week period. Participants will keep a digital diary or diary in paper of their lymphedema related symptoms and experienced issues with the sensors or app.",[27],[169,170,171,172,173],"Resistance Exercise","Compression Therapy","Physical activity","Sedentary time","supervised exercise","2026-04-30",{"date":176,"type":35},"2026-05-06",{"date":178,"type":22},"2026-04",{"date":180,"type":22},"2027-03",{"name":182,"class":77},"Carsten Bogh Juhl",{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":88,"phases":194,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":78},"100548229","clinical-study-to-evaluate-the-effectiveness-and-health-economics-of-a-novel-portable-non-pneumatic-active-compression-device-npcd-for-lymphedemaphlebolymphedema-100548229","NCT06418282","Clinical Study to Evaluate the Effectiveness and Health Economics of a Novel Portable Non-Pneumatic Active Compression Device (NPCD) for Lymphedema\u002FPhlebolymphedema","An Open-label, Multi-center, Prospective VA Study to Evaluate the Effectiveness and Health Economics of a Novel Portable Non-Pneumatic Active Compression Device (NPCD) for Lymphedema\u002FPhlebolymphedema","GRANDE","Inclusion Criteria:\n\n* Males and females ≥ 18 years of age\n* Capable and willing to sign the informed consent and deemed capable of following the study protocol\n* Subjects must have a diagnosis of unilateral or bilateral lower extremity edema or lower extremity lymphedema\u002Fphlebolymphedema as a consequence of chronic venous insufficiency\n* Subjects who have medical clearance using diagnostic confirmation through venous duplex to rule out DVT and superficial\u002Fdeep reflux\n\nExclusion Criteria:\n\n* Inability or unwillingness to participate in all aspects of study protocol and\u002For inability to provide informed consent\n* Individuals with a history or presence of a systemic disorder or condition that could place the subject at increased risk from sequential compression therapy\n* Subjects must not have any diagnosed cognitive or physical impairment that would interfere with the use of the device\n* Non-ambulatory individuals\n* Female: BMI \\> 34 (5'4\", 200 lbs.)\n* Male: BMI \\> 34 (5'9\", 230 lbs.)\n* (Max circumference at patella 58 cm; Max circumference at gluteal fold 75 cm)\n* Diagnosis of lipedema\n* Diagnosis of active or recurrent cancer (\\\u003C 3 months since completion of chemotherapy, radiation therapy or primary surgery for the cancer)\n* Diagnosis of acute infection (in the last four weeks)\n* Diagnosis of active\u002Fopen wound\u002Fulcer\n* Diagnosis of acute thrombophlebitis (in last 2 months)\n* Diagnosis of pulmonary embolism or deep vein thrombosis within the previous 6 months\n* Diagnosis of pulmonary edema\n* Diagnosis of congestive heart failure (uncontrolled\u002Funcompensated)\n* Diagnosis of chronic kidney disease with acute renal failure\n* Diagnosis of epilepsy\n* Subjects with poorly controlled asthma\n* Any condition where increased venous and lymphatic return is undesirable\n* Women who are pregnant, planning a pregnancy or nursing at study entry\n* Participation in any clinical trial of an investigational substance or device during the past 30 days","100 Years",{"count":193,"type":22},100,[90],"An open-label, multi-center, prospective VA study to evaluate the effectiveness and health economics of a Novel Portable Non-Pneumatic Active Compression Device (NPCD) for lymphedema\u002Fphlebolymphedema",[197,27,198],"Phlebolymphedema","Chronic Venous Insufficiency","2026-04-28",{"date":201,"type":35},"2026-05-04",{"date":203,"type":35},"2024-05-13",{"date":205,"type":22},"2027-12-31",{"name":207,"class":42},"Koya Medical, Inc.",{"id":209,"slug":4,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":88,"phases":211,"briefSummary":91,"conditions":212,"keywords":213,"overallStatus":214,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":219,"leadSponsor":221,"locationsCount":4},"100616919",{"count":87,"type":22},[90],[27,93,94,95,96],[98,99,100],"NOT_YET_RECRUITING","2026-03-27",{"date":217,"type":35},"2026-03-31",{"date":199,"type":22},{"date":220,"type":22},"2027-10-28",{"name":41,"class":42},{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":191,"enrollmentInfo":230,"targetDuration":4,"studyType":88,"phases":232,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":78},"100582660","connect-a-multi-cohort-prospective-investigation-of-the-symani-surgical-system-100582660","NCT06866197","CONNECT: A Multi-Cohort, Prospective Investigation of the Symani® Surgical System","A Multi-Cohort, Prospective Investigation of the Symani® Surgical System: A Novel Approach to the Next Frontier of Microsurgery and Expanding Access to Care in Free Tissue Transfer and Lymphatic Surgery","CONNECT","Inclusion Criteria:\n\n* Adults, according to the local law\n* Patient agrees to participate in the study, return for all required follow-up visits, and has willingly provided written informed consent after receiving all information related to the study, its requirements, and the robotic assisted procedure\n* Patient with a clinical indication for a microsurgical anastomosis for a free flap transfer surgery and\u002For lymphatic surgery Investigator considers candidate acceptable for free flap transfer surgery and\u002For lymphatic surgery with a robotic assisted microsurgical anastomosis in accordance with the Symani System IFU\n\nInclusion Criteria for Therapeutic Lymphatic Patients:\n\n* For lymphedema of the extremities, swelling of lymphedema that is not completely reversed by decongestion therapy modalities. (Not applicable for patients with lymphedema of the head and neck)\n* For lymphedema of the extremities, at least one of the following positive quantitative measurements (not applicable for patients with lymphedema of the head and neck):\n\n  1. Volumetry differential between diseased limb and contralateral limb must be at least 10% of the other\n  2. Bioimpedance (L-Dex) differential, if feasible, between diseased limb and contralateral limb of at least 10 units\n* Maintain complete decongestive therapy (CDT), according to International Society of Lymphology (ISL) guidelines, for a minimum duration of four (4) weeks prior to screening\n* Willingness to comply with recommended regimen of self-care, with consistent use of compression garments from screening through the entire study duration\n* Patient must be diagnosed with Lymphedema\n* Patient must have a body mass index (BMI) of ≤ 35\n\nInclusion Criteria for Prophylactic Lymphatic Patients:\n\n* The patient has at least one identifiable risk factor for developing lymphedema of the extremities\n* Patient with a body mass index (BMI) of ≤ 35\n\nExclusion Criteria:\n\n* Patients who are not capable and\u002For unwilling to provide informed consent\n* Clinically significant cardiovascular, digestive, respiratory, endocrine, liver or central nervous system disorders, previous mental disorders, or other disorders that may significantly affect the data collection or the ability to comply with the protocol per the investigators discretion.\n* Known history of significant bleeding, coagulopathy, or Von Willebrand's disease\n* Patients with implanted pacemaker\n* Planned vein graft (either venous or arterial)\n* Previously documented history of chronic kidney disease (eGFR ≤ 30)\n* Currently enrolled in any other investigational clinical studies that the investigator believes may impact patient safety or outcomes\n* Patients belonging to vulnerable populations, such as pregnant women, or patients ineligible to participate for other reasons in the judgement of the investigator\n\nExclusion Criteria for Free Tissue Transfer Patients:\n\n* Patients with buried flaps\n* Multiple flaps planned for the procedure\n\nExclusion Criteria for Therapeutic Lymphatic Patients:\n\n* Patients with venous edema (arising from increased capillary filtration)\n* Patients with other medical conditions that could lead to acute limb edema, such as (but not limited to) acute venous thrombosis or heart failure\n* Current infection in the affected area of lymphedema\n* Current evidence of malignancy\n* Known iodine sensitivity\n* Patient's lymphatic disease is due to lipedema\n* Patients with bilateral lymphedema or lymphedema in multiple anatomical locations\n\nExclusion Criteria for Prophylactic Lymphatic Participants:\n\n* Patients for whom prophylactic surgery on more than one limb is planned\n* Known iodine sensitivity\n* Patients with post-thrombotic syndrome, arterial insufficiency, deep vein thrombosis or any other medical condition that could make them ineligible to participate in the judgment of the investigator\n* Patients diagnosed with lymphedema\n\nIntraoperative Exclusion Criteria:\n\n* Any presenting condition discovered intraoperatively that, in the opinion of the investigator, would make participating in this study not in the patient's best interest\n* The patient does not have at least two robotic sutures attempted during the index procedure",{"count":231,"type":22},180,[90],"The objective of this clinical study is to evaluate the Symani System's safety and effectiveness for microsurgical anastomosis during free tissue transfer surgery and lymphatic surgery.\n\nThe primary endpoints are:\n\nEffectiveness: Clinical Success, defined as intraoperative anastomosis patency. Safety: Freedom from device-related serious adverse events prior to discharge from the index hospitalization, as adjudicated by a Clinical Events Committee.\n\nParticipants will receive treatment as standard of care and be asked to:\n\nAllow the researchers to access and use their information. If participants are undergoing a therapeutic lymphatic procedure, they will be asked to complete a questionnaire and undergo lymphedema volume assessments as part of the study. If participants are undergoing a prophylactic lymphatic procedure, they will only be asked to undergo limb volume assessments.\n\nParticipants will be asked to comply with the follow-up visits as outlined in the protocol.",[29,27,28],{"date":236,"type":35},"2026-04-02",{"date":238,"type":35},"2026-01-20",{"date":240,"type":22},"2029-01-20",{"name":41,"class":42},{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":248,"sex":18,"minAge":249,"maxAge":53,"enrollmentInfo":250,"targetDuration":4,"studyType":88,"phases":252,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":78},"100519316","effects-of-extracorporeal-shock-wave-therapy-and-pulse-electromagnetic-field-therapy-on-lymphoedema-100519316","NCT06041958","Effects of Extracorporeal Shock Wave Therapy and Pulse Electromagnetic Field Therapy on Lymphoedema","Inclusion Criteria:\n\n* Participants must be at least 20 years old and have no significant cognitive, language comprehension, or communication issues, be able to understand and follow instructions, and sign the informed consent form.\n* Individuals with lymphedema after treatment for breast cancer or gynecologic cancer are eligible (lymphedema is defined as a circumference difference of \\>2 cm in the same location on both limbs).\n* You must be able to attend follow-up appointments at specific times during the 12 months of the trial, referred by a rehabilitation physician in the outpatient department.\n\nExclusion Criteria:\n\n* The affected limb has unhealed open wounds, acute infections, or other conditions unsuitable for contact-based treatment.\n* The affected limb has metastatic tumors.\n* The affected limb has untreated deep vein thrombosis.\n* Severe clotting abnormalities.",true,"20 Years",{"count":251,"type":22},90,[90],"Lymphedema occurs not only in patients with breast cancer and gynecological cancers but also in those where lymphatic drainage is obstructed. Accumulation of lymphatic fluid within tissues results in limb swelling. Additionally, proteins present in lymphatic fluid might lead to fibrosis within tissues, causing various challenges for patients. The changes in volume and weight can significantly impact daily life activities such as eating, brushing teeth, and other routine tasks. Furthermore, it can lead to clothing difficulties and provoke unwanted attention due to aesthetic concerns.\n\nCurrently, there is no definitive treatment for lymphedema. However, prospective research has shown promising results in applying extracorporeal shock wave therapy (ESWT), originally used for musculoskeletal disorders like plantar fasciitis, tennis elbow, frozen shoulder, and non-union fractures, to lymphedema patients. Similarly, Pulse Electromagnetic Field Therapy (PEMFT), widely used for pain management and muscle strengthening, has the potential for treating lymphedema as it can enhance blood circulation and stimulate muscle contractions.\n\nThis research project aims to explore the effectiveness and sustainability of using ESWT and PEMFT for lymphedema patients. By applying these therapies to lymphedema patients, this study aims to evaluate their treatment outcomes and long-term effects.",[27],"2026-03-26",{"date":217,"type":35},{"date":258,"type":35},"2021-10-08",{"date":260,"type":22},"2026-12-31",{"name":262,"class":77},"Zheng-Yu Hoe, MD., PhD.",{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":272,"conditions":273,"keywords":278,"overallStatus":214,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":78},"100631299","detecting-the-undetected-heart-failure-screening-at-the-lymphoedema-point-of-care-100631299","NCT07498868","Detecting the Undetected: Heart Failure Screening at the Lymphoedema Point of Care","Detecting the Undetected: an Observational Cohort Study Evaluating the Health Economics, Clinical Utility, and Patient and Staff Experiences of Innovative Peptide Testing to Screen for Heart Failure in Lymphoedema Clinics","Inclusion Criteria:\n\n* Patient of Swansea Bay University Health Board Lymphoedema Service.\n* Consent to participate in the study.\n* Bilateral lower limb oedema.\n* Aged 18-years or older.\n* Able to provided informed consent to be involved.\n* No diagnosis of heart failure.\n* No NT-proBNP test in the previous 12-months OR increase in lymphoedema severity since an NT-proBNP test in the last 12-months.\n\nExclusion Criteria:\n\n* All inclusion criteria not met.\n* Not a lymphoedema patient in Swansea Bay University Health Board Lymphoedema Service.\n* Unable to consent for themselves.\n* Women who are pregnant or have given birth in the last 6-months.\n* Patients with an existing heart failure diagnosis.",{"count":271,"type":22},618,"Heart failure affects more people than the four most common cancers combined. When identified early, management is more straightforward, preventing complications, hospitalisations, and fatalities. Breathlessness and fatigue are cardinal symptoms of heart failure that can present in a number of conditions. As a result, leg swelling, the third cardinal symptom, is the first noted in many people. The presence of leg swelling leads to patients being seen in lymphoedema clinics before the need for cardiology investigation has been identified. Lymphoedema is the presence of chronic oedema as a result of congenital abnormalities, inflammation, infection, trauma, or cancer and its treatments. The vast majority of lymphoedema patients have swelling in their legs.\n\nA recent study has shown that 9.4% lymphoedema patients need to be investigated for heart failure. At present, the need for investigation is identified by performing a laboratory blood test, which takes time to arrange and complete. An alternate point of care test can provide a result in 12-minutes at the lymphoedema appointment, and enable appropriate action to be taken. This can reduce the demands on primary care and shorten the chain of events to a specialist assessment, as well as reducing inappropriate referrals.\n\nThis research, funded by NHS Wales Performance and Improvement, will perform a point of care test to screen for possible heart failure in lymphoedema clinics and establish the clinical utility by exploring the experiences of patients and staff involved and determining the health economic benefits. A supplementary aim is to compare the point of care test to the currently used laboratory test in a subsample to promote confidence in the test and support efforts to spread and scale across all health boards in Wales on completion.",[274,27,275,276,277],"Lymphedema, Lower Limb","Heart Failure","Heart Failure (for Example, Fluid Overload)","Heart Failure (HF)",[279,280,281,282,283,284,285,286,287],"lymphoedema","heart failure","undetected heart failure","undiagnosed heart failure","bilateral lower limb oedema","bilateral leg oedema","point of care testing","screening","NT-proBNP","2026-03-23",{"date":215,"type":35},{"date":291,"type":22},"2026-05",{"date":293,"type":22},"2028-09",{"name":295,"class":77},"Swansea Bay University Health Board",{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":248,"sex":51,"minAge":52,"maxAge":114,"enrollmentInfo":303,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":305,"conditions":306,"keywords":308,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":319,"leadSponsor":321,"locationsCount":78},"100630559","multimodal-ultrasound-for-differentiating-lymphedema-and-lipedema-100630559","NCT07489248","Multimodal Ultrasound for Differentiating Lymphedema and Lipedema","ULTRASONOGRAPHIC EVALUATION OF LOWER EXTREMITY SKIN AND SUBCUTANEOUS TISSUE WITH QUANTITATIVE ECHOGENICITY AND ELASTOGRAPHY IN LYMPHEDEMA, LIPEDEMA, AND HEALTHY CONTROL GROUPS: A CONTROLLED CLINICAL STUDY","Inclusion Criteria:\n\nIndividuals aged 18 to 75 years.\n\nClinical diagnosis of lower extremity lymphedema (for the lymphedema group).\n\nClinical diagnosis of lower extremity lipedema (for the lipedema group).\n\nHealthy individuals with no history or clinical signs of chronic lower extremity edema (for the control group).\n\nExclusion Criteria:\n\nPresence of active local infections, such as cellulitis or erysipelas, in the lower extremities.\n\nHistory of deep vein thrombosis (DVT) or severe chronic venous insufficiency.\n\nSystemic conditions that can cause secondary edema, including congestive heart failure, chronic kidney disease, or severe hepatic impairment.\n\nPrevious surgical interventions on the affected lower extremities, including liposuction, lymphatic reconstructive surgery, or major orthopedic surgeries.\n\nActive malignancy or currently undergoing radiotherapy\u002Fchemotherapy.\n\nPregnancy or lactation.",{"count":304,"type":22},75,"The aim of this observational study is to evaluate the diagnostic value of multimodal ultrasonography in differentiating between lymphedema and lipedema. Differentiating these two chronic conditions based solely on clinical examination can be challenging due to overlapping symptoms. This study will utilize various non-invasive ultrasound techniques-including B-mode ultrasound, strain elastography, power Doppler, and quantitative ImageJ analysis-to compare tissue characteristics among patients with lymphedema, patients with lipedema, and healthy controls. The goal is to identify reliable, non-invasive imaging biomarkers that can facilitate early and accurate diagnosis, thereby optimizing patient management.",[27,307],"Lipedema",[309,310,311,312,313,314],"Multimodal Ultrasonography","Strain Elastography","Differential Diagnosis","Power Doppler","ImageJ Analysis","Subcutaneous Tissue","2026-03-19",{"date":317,"type":35},"2026-03-24",{"date":315,"type":35},{"date":320,"type":22},"2026-09-15",{"name":322,"class":323},"Kayseri City Hospital","OTHER_GOV",{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":332,"targetDuration":333,"studyType":23,"phases":4,"briefSummary":334,"conditions":335,"keywords":337,"overallStatus":214,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":78},"100630268","lymphoedema-diagnosis-and-treatment-100630268","NCT07485465","Lymphoedema Diagnosis and Treatment","The Role of Chat GPT in the Diagnosis and Treatment of Lymphedema","CDTL","Inclusion Criteria:\n\n* Patients over the age of 18\n* Clinical diagnosis of lymphoedema\n* Clinical diagnosis of lipoedema\n* Clinical diagnosis of venous insufficiency\n\nExclusion Criteria:\n\n* Lack of medical history\n* Lack of demographic data\n* Lack of clinical data and\n* Lack of imaging methods",{"count":7,"type":22},"1 Day","A domain-specific, custom-trained large language model for the differential diagnosis and treatment planning of lymphedema, lipedema, and venous insufficiency.",[27,336],"Artificial Intelligence (AI)",[98,338,339],"chat gpt","artificial intelligence","2026-03-17",{"date":342,"type":35},"2026-03-20",{"date":344,"type":22},"2026-03-15",{"date":346,"type":22},"2026-04-01",{"name":348,"class":77},"Fatih Sultan Mehmet Training and Research Hospital",{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":355,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":357,"enrollmentInfo":358,"targetDuration":4,"studyType":88,"phases":360,"briefSummary":361,"conditions":362,"keywords":366,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":381},"100629274","impact-of-virtual-reality-vr-based-exercises-on-lower-limb-lymphedema-outcomes-lelo-100629274","NCT07472543","Impact of Virtual Reality (VR) Based Exercises on Lower Limb Lymphedema Outcomes (LELO)","The Effect of Virtual Reality-Assisted Exercises on Gait Parameters, Function, Quality of Life, and Edema Level in Patients With Lower Extremity Lymphedema","VR-LELO","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Diagnosis of unilateral lower extremity lymphedema following gynecological and\u002For oncological surgery\n* Stage 2 or 3 lymphedema\n\nExclusion Criteria:\n\n* Decompensated heart, lung, or kidney failure\n* Uncontrolled hypertension\n* Presence of systemic infection\n* Local infections in the lower extremity such as erysipelas or cellulitis\n* Venous insufficiency (e.g., deep vein thrombosis)\n* Any neuromuscular or orthopedic disease affecting lower extremity walking\n* Presence of balance disorders\n* Bilateral lymphedema\n* Presence of lipolymphedema\n* Fracture in the lower extremity\n* Active metastasis\n* Speech or language problems\n* Pregnancy\n* Inability to continue treatment (5 days a week for a total of 4 weeks)","65 Years",{"count":359,"type":22},40,[90],"This randomized controlled study aims to investigate the effects of virtual reality (VR)-assisted gait training, in addition to Complex Decongestive Therapy (CDT), on gait parameters, physical function, quality of life, and edema levels in patients with lower extremity lymphedema. Lymphedema is a progressive condition characterized by the accumulation of protein-rich fluid due to lymphatic drainage insufficiency, leading to chronic inflammation and fibrosis. It impairs gait patterns and reduces functional mobility. VR technologies, such as the RehaWalk system, provide interactive, personalized rehabilitation environments that enhance motor learning, motivation, and adherence to treatment. The study evaluates spatiotemporal gait parameters, three-zone foot analysis (heel, midfoot, forefoot), limb circumferences, ultrasound measurements (dermis, epidermis, subcutaneous fat thickness), and patient-reported outcomes. VR-based training offers a novel, engaging approach to improve physical rehabilitation outcomes in patients with lower limb lymphedema. No significant risks are expected in this study.",[27,363,364,365],"Gait Dysfunction","Physical Rehabilitation","Chronic Edema",[98,367,368,369,370,371],"virtual reality exercises","ultrasonography","Gait Analysis","Spatiotemporal Parameters","Complex Decongestive Therapy (CDT)","2026-03-13",{"date":374,"type":35},"2026-03-16",{"date":376,"type":35},"2025-09-01",{"date":378,"type":22},"2026-10-01",{"name":380,"class":77},"Gaziler Physical Medicine and Rehabilitation Education and Research Hospital",2,{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":389,"targetDuration":390,"studyType":23,"phases":4,"briefSummary":391,"conditions":392,"keywords":397,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":409,"locationsCount":78},"100629294","longitudinal-body-composition-assessment-in-breast-cancer-patients-100629294","NCT07472803","Longitudinal Body Composition Assessment in Breast Cancer Patients","Long-term Evaluation of the Body Composition and the Impact of Resistance and Relaxation Exercise on Muscle Mass and Quality of Life in Patients With Breast Cancer","Inclusion Criteria:\n\n* \\>18 years of age\n* Diagnosed with stage I-III non-metastatic breast cancer within 12 months of diagnosis\n* Scheduled for surgery, chemotherapy, with or without radiotherapy or targeted therapy.\n\nExclusion Criteria:\n\n* Women diagnosed with metastatic (stage IV) breast cancer\n* Women planning to move away from the area or be away for more than 6 months during the study period\n* Women planning to become pregnant during the study period\n* Implantable devices (e.g., pacemaker, nerve stimulator) or surgical implants (e.g., total hip or knee replacements)",{"count":193,"type":22},"12 Months","This observational cohort study aims to track longitudinal changes in body composition, including skeletal muscle mass and fat distribution, in patients diagnosed with breast cancer. Following primary surgery and adjuvant therapy, participants will be monitored over a 2-year period.\n\nThe primary objective is to evaluate the natural progression of skeletal muscle mass index (SMI) and metabolic changes in this population. By conducting serial measurements, this study seeks to characterize the longitudinal trends in muscle loss and body composition shifts post-treatment, providing data to better understand the physiological impact of the cancer recovery process.",[393,394,395,396,27],"Breast Neoplasms","Body Composition","Sarcopenia","Fat Redistribution",[398,399,394,400,401,402,403],"Breast Cancer Survivors","Post-Treatment Recovery","Longitudinal Cohort Study","Skeletal Muscle Mass Index","Metabolic Monitoring","sarcopenia","2026-03-12",{"date":374,"type":35},{"date":407,"type":35},"2025-05-19",{"date":205,"type":22},{"name":410,"class":77},"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation",{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":248,"sex":51,"minAge":52,"maxAge":418,"enrollmentInfo":419,"targetDuration":4,"studyType":88,"phases":420,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":78},"100627425","investigation-of-the-effectiveness-of-progressive-resistance-exercise-training-in-the-management-of-lymphedema-100627425","NCT07448467","Investigation of the Effectiveness of Progressive Resistance Exercise Training in the Management of Lymphedema.","Investigating the Effectiveness of Progressive Resistance Exercise Training in the Management of Lymphedema Developing After Breast Cancer Treatment: a Randomized Controlled Trial","Inclusion criteria:\n\n* Being between 18 and 60 years of age.\n* Being included in the study 3 months after undergoing surgery.\n* Being able to tolerate compression bandages or compression garments.\n\nExclusion criteria:\n\n\\- Individuals who need to restart active cancer treatment during the study period. - Being within the first 3 months after surgery.","60 Years",{"count":5,"type":22},[90],"This study aims to investigate the effect of progressive resistance exercise training on the clinical findings and functional outcomes of lymphedema in individuals who develop upper extremity lymphedema after breast cancer treatment (surgery, chemotherapy and\u002For radiotherapy).",[27,67],"2026-03-10",{"date":404,"type":35},{"date":426,"type":35},"2026-03-06",{"date":428,"type":22},"2026-08-30",{"name":430,"class":77},"Uskudar University",{"id":432,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":434,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":439,"leadSponsor":440,"locationsCount":441},"100571805",{"count":21,"type":22},[26,27,28,29,30],"2026-03-04",{"date":437,"type":35},"2026-03-05",{"date":37,"type":35},{"date":39,"type":22},{"name":41,"class":42},4,{"id":443,"slug":4,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":4,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":18,"minAge":249,"maxAge":418,"enrollmentInfo":448,"targetDuration":4,"studyType":88,"phases":450,"briefSummary":451,"conditions":452,"keywords":454,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":78},"100624821","NCT07414615","Aerobic Training in Lower Extremity Lymphedema","The Effect of Aerobic Training on Gait, Postural Control, Lower Extremity Muscle Strength and Functionality in Patients With Lower Extremity Lymphedema","Inclusion Criteria:\n\n* Aged between 20 and 60 years\n* Diagnosed with bilateral lower extremity lymphedema\n* Completion of chemotherapy, radiotherapy, or other oncological treatments, with no oncological contraindication to participation\n* Signed written informed consent\n* Willingness to participate in the study\n\nExclusion Criteria:\n\n* Presence of uncontrolled cardiac or pulmonary disease\n* Presence of renal insufficiency\n* Presence of musculoskeletal or neurological disorders affecting mobility or balance\n* Presence of systemic or local infection in the lower extremity\n* Impaired independent ambulation or use of assistive walking devices\n* Pregnancy\n* Presence of visual, cognitive, or intellectual impairment that may interfere with participation in assessment or intervention procedures",{"count":449,"type":22},24,[90],"This randomized controlled study aims to evaluate the effects of aerobic exercise training on gait, postural control, lower extremity muscle strength, and functional status in individuals with bilateral lower extremity lymphedema. A total of 24 participants aged between 20 and 60 years with a diagnosis of bilateral lower extremity lymphedema will be randomly assigned to either an aerobic exercise group or a control group. The aerobic exercise group will receive aerobic exercise training in addition to Complex Decongestive Therapy (CDT), while the control group will receive CDT alone.\n\nLower extremity edema will be assessed using circumferential measurements taken from the ankle to the inguinal region. Gait function will be evaluated through angular and spatiotemporal analysis using Kinovea software, including parameters such as step length, walking speed, and double support time. Postural control will be assessed using the Balance Error Scoring System (BESS) and the Timed Up and Go Test. Lower extremity muscle strength and endurance will be evaluated using Manual Muscle Testing and the 30-Second Sit-to-Stand Test. Functional status of the lower extremities will be assessed using the Lower Extremity Functional Scale (LEFS).",[27,453],"Lymphedema Lower Extremity",[27,455,456,457,458,459],"Lower Extremity","Gait","Postural Control","Muscle Strength","Functionality","2026-02-17",{"date":462,"type":35},"2026-02-19",{"date":464,"type":35},"2026-02-16",{"date":466,"type":22},"2026-04-10",{"name":468,"class":77},"Bezmialem Vakif University",{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":476,"targetDuration":4,"studyType":88,"phases":477,"briefSummary":479,"conditions":480,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":481,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":78},"100592105","phase-2-lymphedema-prevention-through-immediate-lymphatic-reconstruction-lily-trial-100592105","NCT06989099","Lymphedema Prevention Through Immediate Lymphatic Reconstruction (LILY) Trial.","Lymphedema Prevention Through Immediate Lymphatic Reconstruction (LILY) Trial","Inclusion Criteria:\n\n1. Participants diagnosed with IBC.\n2. Participants who have been scheduled for ILR\u002FpLVB by their treating physician\u002Fsurgeon at the time of their axillary lymphadenectomy for breast cancer\n3. Participants willing and able to comply with the study protocol requirements and all study-related visit requirements.\n4. Female subjects at least 18 years old and capable of providing consent to participate.\n5. Females of childbearing potential must have a negative urine pregnancy test within 36 hours prior to study drug administration and agree to use a medically accepted method of contraception for a period of one month following the study.\n\nExclusion Criteria:\n\n1. Patients known to be pregnant or breast-feeding.\n2. Patients with known or suspected iodine or ICG hypersensitivity.\n3. Patients unable to remain stationary for one hour.\n4. Active cellulitis.\n5. Subjects with a preoperative clinical lymphedema diagnosis.\n6. Subjects undergoing bilateral ALND.\n7. Subjects requiring immediate chest wall reconstruction with a pedicled or microvascular flap, or those that have received preoperative radiation therapy.\n8. Patients with BMI \\>45kg\u002Fm2.",{"count":5,"type":22},[478],"PHASE2","To learn if reconstruction of the lymphatic system at the time of axillary lymphadenectomy can reduce the risk of developing lymphedema.",[27],{"date":462,"type":35},{"date":483,"type":35},"2024-09-24",{"date":485,"type":22},"2029-08-01",{"name":487,"class":77},"M.D. Anderson Cancer Center",{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":18,"minAge":495,"maxAge":496,"enrollmentInfo":497,"targetDuration":4,"studyType":88,"phases":498,"briefSummary":499,"conditions":500,"keywords":503,"overallStatus":214,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":512,"leadSponsor":514,"locationsCount":4},"100625144","infant-massage-for-lymphedema-and-comfort-in-preterm-newborns-100625144","NCT07418814","Infant Massage for Lymphedema and Comfort in Preterm Newborns","The Effectiveness of Infant Massage in Reducing Immobilization-Related Lymphedema Symptoms and Increasing Comfort in Preterm Newborns","Inclusion Criteria:\n\nTo ensure a homogenous and clinically stable sample, infants meeting the following criteria will be recruited:\n\n* Clinical diagnosis of lymphedema.\n* Hemodynamic and clinical stability.\n* No current or recent (within 24 hours) administration of analgesic or sedative medications that could mask comfort assessments.\n* Intact skin integrity with no contraindications for topical massage.\n* Absence of congenital heart disease or neurological disorders (antenatal or postnatal diagnosis).\n* No immediate requirement for endotracheal aspiration.\n* Requirement for only non-invasive respiratory support (e.g., nCPAP).\n* Provision of written informed consent by the legal guardians (parents).\n\nExclusion Criteria:\n\nInfants will be excluded if they present with:\n\n* Major congenital anomalies.\n* Severe respiratory, cardiac, or neurological instability during the study period.\n* Any acute medical contraindication identified by the attending neonatologist.","28 Weeks","37 Weeks",{"count":359,"type":22},[90],"This randomized controlled trial investigates the effectiveness of infant massage in reducing symptoms of immobilization-related lymphedema and improving comfort in preterm newborns hospitalized in the Neonatal Intensive Care Unit (NICU). Preterm infants frequently develop lymphedema due to their immature circulatory systems and prolonged lack of movement.\n\nThe study compares two groups of infants: one receiving standard care and another receiving a daily 15-minute massage therapy session for 14 consecutive days in addition to standard care. Researchers will evaluate the impact of the massage by measuring the circumference of the infants' wrists, elbows, ankles, and knees to assess fluid reduction. Additionally, the infants' comfort levels will be assessed using the Premature Infant Comfort Scale (PICS). The goal is to determine if massage can serve as a safe, non-invasive method to manage lymphedema and reduce distress in this vulnerable population.",[27,501,62,502],"Premature Birth","Immobilization",[504,505,27,506,507,502],"Infant Massage","Preterm Infant","Neonatal Comfort","Massage Therapy","2026-02-11",{"date":510,"type":35},"2026-02-18",{"date":346,"type":22},{"date":513,"type":22},"2027-04-01",{"name":515,"class":77},"Erzurum Technical University",{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":522,"targetDuration":4,"studyType":88,"phases":524,"briefSummary":525,"conditions":526,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":528,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":78},"100554055","phase-2-systemic-therapy-of-open-label-prophylactic-pravastatin-or-pentoxifyllinetocopherol-prevention-of-lymphedema-advancing-to-eventual-fibrosis-an-interventional-registry-embedded-bayesian-randomized-trial-for-radiation-sequelae-stop4-late-fibrose-100554055","NCT06494111","Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline\u002FTocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)","Inclusion Criteria:\n\n• Untreated T0-T4N0-3M0 oropharyngeal squamous carcinoma.\n\n1. Dispositioned to radiotherapy with prescribed dose to unilateral or bilateral neck(s).\n2. Creatinine clearance \\>30mL\u002Fmin\n3. Age ≥18 years. Because no dosing or adverse event data are currently available on the use of pentoxifylline\u002Fpravastatin in participants \\\u003C18 years of age, children are excluded from this study\n4. ECOG performance status ≤2 (Karnofsky ≥60%,)\n5. Participants must have adequate organ and marrow function as defined below\n\n   * absolute neutrophil count ≥1,000\u002FmcL\n   * platelets ≥100,000\u002FmcL\n   * total bilirubin ≤ institutional upper limit of normal (ULN)\n   * AST(SGOT)\u002FALT(SGPT) ≤3 x institutional ULN\n   * creatinine ≤1.5 x institutional ULN\n6. The effects of pentoxifylline\u002Fpravastatin on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female participants, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following.\n\n   * Postmenopausal (no menses in greater than or equal to 12 consecutive months).\n   * History of hysterectomy or bilateral salpingo-oophorectomy.\n   * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).\n   * History of bilateral tubal ligation or another surgical sterilization procedure.\n   * Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject\u002FPartner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n7. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Active liver disease (Child-Pugh class B-C), cirrhosis, nor active alcoholism.\n2. History of myopathy\u002Frhabdomyolysis.\n3. History of acute myocardial infarction or severe coronary disease.\n4. Pregnant\u002Fpost-menopausal, or male.\n5. History of diabetes mellitus.\n6. Allergy\u002Fhypersensitivity to Hydroxymethylglutaryl-coenzyme A (HMG Co-A) reductase inhibitor and\u002For xanthine derivatives, e.g., caffeine, theophylline, theobromine.\n7. Contraindications for MRI\n8. Participants who are receiving any other investigational agents.\n9. History of allergic reactions attributed to compounds of similar chemical or biologic composition to statins, hemorheologic agents or other agents used in study\n10. Participants with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.",{"count":523,"type":22},295,[478],"To learn if pentoxifylline and vitamin E or pravastatin can reduce radiation-induced lymphedema\u002Ffibrosis.",[27,527],"Fibrosis",{"date":529,"type":35},"2026-02-13",{"date":531,"type":35},"2025-02-13",{"date":533,"type":22},"2031-03-01",{"name":487,"class":77},{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":539,"acronym":4,"eligibilityCriteria":540,"healthyVolunteers":12,"sex":51,"minAge":4,"maxAge":4,"enrollmentInfo":541,"targetDuration":4,"studyType":88,"phases":543,"briefSummary":544,"conditions":545,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":78},"100586237","phase-2-reversing-external-beam-radiotherapy-associated-fibrosis-syndrome-an-interventional-bayesian-adaptive-randomized-controlled-orphan-drug-platform-trial-for-orodental-sequelae-reverse-fibrose-100586237","NCT06912763","Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)","Eligibility Criteria Eligibility criteria (observational registry or randomization)\n\n1. Prior history of head and neck cancer with no active disease.\n2. Treated previously with radiotherapy with prescribed dose (greater or equal to 30Gy) to unilateral or bilateral neck(s)\n3. Detectable CTC-AE G2+ lymphedema\u002Ffibrosis at \\>6 months post-radiotherapy.\n4. No active liver disease (Child-Pugh class B-C), cirrhosis, nor active alcoholism, nor history of ulcers.\n5. No history of myopathy\u002Frhabdomyolysis.\n6. Creatinine clearance \\\u003C30mL\u002Fmin.\n7. No history of acute myocardial infarction or severe coronary disease.\n8. Non-pregnant\u002Fpost-menopausal, or male.\n9. No history of diabetes mellitus\n10. Allergy\u002Fhypersensitivity to HMG Co-A reductase inhibitor and\u002For xanthine derivatives, e.g., caffeine, theophylline, theobromine\n11. No contraindications for magnetic resonance imaging a Subject to the discretion of the treating physician and Principal Investigator (PI), as the MRI may be optional\n\nExclusion Criteria\n\n1. Active liver disease (Child-Pugh class B-C), cirrhosis, nor active alcoholism.\n2. History of myopathy\u002Frhabdomyolysis.\n3. History of acute myocardial infarction or severe coronary disease.\n4. Pregnant\u002Fpost-menopausal, or male.\n5. History of diabetes mellitus.\n6. Allergy\u002Fhypersensitivity to Hydroxymethylglutaryl-coenzyme A (HMG Co-A) reductase inhibitor and\u002For xanthine derivatives, e.g., caffeine, theophylline, theobromine.\n7. Contraindications for MRI Subject to the discretion of the treating physician and Principal Investigator (PI), as the MRI may be optional\n8. Participants who are receiving any other investigational agents.\n9. History of allergic reactions attributed to compounds of similar chemical or biologic composition to statins, hemorheologic agents or other agents used in study\n10. Participants with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.",{"count":542,"type":22},250,[478],"To find out if adding medication can help treat or prevent lymphedema and\u002For fibrosis related to radiation therapy, in survivors of head and neck cancer. Researchers will compare these drugs to find the most effective therapy for preventing or limiting these side effects.",[546,27,547,527],"Fibrosis Syndrome","Head &Amp; Neck Cancer","2026-01-23",{"date":550,"type":35},"2026-01-26",{"date":552,"type":35},"2025-08-08",{"date":554,"type":22},"2033-03-01",{"name":487,"class":77},{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":114,"enrollmentInfo":563,"targetDuration":4,"studyType":88,"phases":565,"briefSummary":566,"conditions":567,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":78},"100487587","study-of-lymphatic-dysfunction-in-primary-and-secondary-lymphedema-100487587","NCT05629026","Study of Lymphatic Dysfunction in Primary and Secondary Lymphedema","LYMPHODYS","Inclusion Criteria:\n\n1. Patients in who developed primary lymphedema or secondary lymphedema after breast cancer treatment.\n2. Male and female over the age of 18 and under 75.\n3. Patient affiliated to a social security scheme in France.\n4. Patient having signed informed consent prior to inclusion in the study and prior to any specific procedure for the study.\n5. Patients with no recidive \\> 3 years after cancer surgery.\n6. Patients with Body Mass Index \\\u003C35.\n7. Patient enrolled in a care pathway for the management of their lymphedema (medical and educational care).\n8. Patients wearing a compression orthosis on the limb with lymphedema.\n\nExclusion Criteria:\n\n1. Patients with strong suspicion or with active bacterial or fungal infection.\n2. Patient with venous insufficiency associated with lymphedema.\n3. Patient with a history of deep venous thrombosis on the limb with lymphedema.\n4. History of chronic inflammatory disease.\n5. Active neoplasia during parallel management.\n6. Patient already included in another therapeutic trial.\n7. Pregnant or breastfeeding woman.\n8. Metastatic cancer.\n9. Bilateral breast cancer.\n10. Obliterative arterial disease.\n11. Multiple erysipelas.\n12. Active smoking (delayed healing).\n13. Medicines that may promote delayed healing (Corticosteroid therapy, immunosuppressants).\n14. Medication that thins the blood (aspirin and antiplatelet agent, anti-coagulant).\n15. Betadine allergy.\n16. Patient under guardianship or trusteeship, persons placed under the protection of justice",{"count":564,"type":22},60,[90],"Lymphedema is a disorder of the lymphatic vascular system characterized by impaired lymphatic return and swelling of the extremities and accumulation of undrained interstitial fluid\u002Flymph that results in fibrosis and adipose tissue deposition in the affected area. It can be an inherited condition (primary lymphedema) or occurs after cancer surgery and lymph node removal (secondary lymphedema). It causes a significant morbidity and is a common disabling disease affecting more than 200 million people worldwide, however there is no curative treatment for primary or secondary lymphedema.",[27],"2025-12-23",{"date":570,"type":35},"2025-12-31",{"date":572,"type":35},"2024-02-21",{"date":574,"type":22},"2026-02",{"name":576,"class":77},"University Hospital, Toulouse",{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":4,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":584,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":586,"conditions":587,"keywords":588,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":591,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":597,"locationsCount":78},"100172689","prospective-screening-for-breast-cancer-related-lymphedema-100172689","NCT01521741","Prospective Screening for Breast Cancer-related Lymphedema","Prospective Screening for Breast Cancer-related Lymphedema: Analysis of Objective Measurements, Symptoms, Functionality, and Quality of Life Questionnaires to Evaluate Lymphedema in Patients Following Treatment for Breast Cancer.","Inclusion Criteria:\n\n* Confirmed diagnosis of breast cancer\n* Ability to obtain physical positioning for perometry (e.g. abducting shoulder to 90 degrees) and BIS measurements (e.g. standing without aid)\n\nExclusion Criteria:\n\n* Evidence of distant metastatic disease that may cause edema,\n* Previous breast cancer\n* History of lymphedema\n* Pregnancy at the time of accrual and\u002For cardiac implants (contraindications for BIS)\n* Medical conditions that cause fluid retention or swelling (e.g. axillary cancer recurrence, renal insufficiency, congestive heart failure).",{"count":585,"type":22},10000,"The primary objectives of this study are twofold: 1) to detect and determine the level of symptoms, functional disability, and changes in quality of life that breast cancer patients experience from changes in their arms during and after treatment for breast cancer by collecting patient reported outcome measures, objective measurements, and clinical information in a prospectively maintained database and 2) to improve breast cancer-related lymphedema outcomes by early detection using objective measurements and symptoms assessments and assess these outcomes by maintaining the data in a database in order to contribute to the literature. The secondary aim of this study is to assess extracellular fluid content in the upper extremity, breast, and\u002For trunk of patients treated for breast cancer before, during, and after treatment in order to better understand the role of bioimpedance spectroscopy in lymphedema screening.",[27],[67,27,589,590],"Symptoms","Screening",{"date":592,"type":35},"2025-12-24",{"date":594,"type":4},"2009-08",{"date":596,"type":22},"2026-12",{"name":76,"class":77},{"id":599,"slug":600,"hasResults":12,"nctId":601,"briefTitle":602,"officialTitle":603,"acronym":4,"eligibilityCriteria":604,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":605,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":607,"conditions":608,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":628,"leadSponsor":630,"locationsCount":78},"100487581","vascular-lab-resource-vlr-biorepository-100487581","NCT05628948","Vascular Lab Resource (VLR) Biorepository","Vascular Lab Resource (VLR) Biorepository Study","Inclusion Criteria:\n\n1. 18 years or older\n2. Subjects capable of providing informed consent document\n3. Subjects with diagnosed with or at risk for cardiovascular and metabolic diseases\n\nExclusion Criteria:\n\n1. Known life expectancy of ≤ 6 months at the time of enrollment\n2. Known current pregnancy\n3. Severe Anemia (last documented hemoglobin \\\u003C 7.0 g\u002FdL)",{"count":606,"type":22},500,"This is a study of biomarkers obtained from prospectively collected subject samples and their correlation with cardiovascular and metabolic diseases. The purpose of this initiative is to develop an enduring tool to allow for collaborative research between clinicians at Cleveland Clinic Main Campus and basic scientists at the Lerner Research Institute. This collaboration will allow resources to be available to clinical and basic researchers alike. This tool will enable research of vascular disease in the Vascular Lab and will leverage this valuable asset to the fullest extent to allow for interdepartmental collaboration.",[609,610,611,612,613,614,615,27,307,616,617,618,619,620,621,622],"Cardiovascular Diseases","Metabolic Disease","Peripheral Artery Disease","Carotid Disease","Aneurysmal Disease","Venous Disease","Thrombosis","Non-Atherosclerotic Chronic Arterial Occlusive Disease","Vasculitis","Fibromuscular Dysplasia","Arterial Dissection","May-Thurner Syndrome","Thoracic Outlet Syndrome","Vasospasm","2025-12-15",{"date":625,"type":35},"2025-12-19",{"date":627,"type":35},"2019-11-14",{"date":629,"type":22},"2031-06-30",{"name":631,"class":77},"The Cleveland Clinic"]